Challenges to medications development in treating alcohol dependence: An international perspective - Summary of a symposium held at the ESBRA Congress, Prague, 13 September 2003
(2004) In Alcohol and Alcoholism 39(4). p.271-275- Abstract
- Few medications for treating alcohol dependence exist. Greater partnership is needed between academia and the pharmaceutical industry to develop, licence and market efficacious medications for treating alcohol dependence. Methodologies that span the divide between preclinical and large-scale clinical studies need to be developed in order to provide sufficient information on safety, toleration, drug-interaction profile and efficacy, with which to guide development decisions. Due to the heterogeneous nature of alcohol dependence, the effort of developing an efficacious medication is likely to be enhanced by clearer choices about the characteristics of the population. Careful consideration of potential mechanism of action of the putative... (More)
- Few medications for treating alcohol dependence exist. Greater partnership is needed between academia and the pharmaceutical industry to develop, licence and market efficacious medications for treating alcohol dependence. Methodologies that span the divide between preclinical and large-scale clinical studies need to be developed in order to provide sufficient information on safety, toleration, drug-interaction profile and efficacy, with which to guide development decisions. Due to the heterogeneous nature of alcohol dependence, the effort of developing an efficacious medication is likely to be enhanced by clearer choices about the characteristics of the population. Careful consideration of potential mechanism of action of the putative therapeutic medication should enable the appropriate choice of drinking endpoint. The pharmaceutical industry in collaboration with academia might need to develop new approaches to determining appropriate treatment endpoints with regulatory bodies. The investment risk to industry should be appraised not only in terms of the rather poor results of previous marketing efforts but with a view to the opportunity to penetrate a potentially enormous and largely untapped market. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/273623
- author
- organization
- publishing date
- 2004
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Alcohol and Alcoholism
- volume
- 39
- issue
- 4
- pages
- 271 - 275
- publisher
- Oxford University Press
- external identifiers
-
- wos:000222270300001
- scopus:3242762314
- ISSN
- 1464-3502
- DOI
- 10.1093/alcalc/agh067
- language
- English
- LU publication?
- yes
- id
- 247715bd-96c2-4c24-9b6d-cd320470e292 (old id 273623)
- date added to LUP
- 2016-04-01 11:41:22
- date last changed
- 2022-04-28 18:33:27
@article{247715bd-96c2-4c24-9b6d-cd320470e292, abstract = {{Few medications for treating alcohol dependence exist. Greater partnership is needed between academia and the pharmaceutical industry to develop, licence and market efficacious medications for treating alcohol dependence. Methodologies that span the divide between preclinical and large-scale clinical studies need to be developed in order to provide sufficient information on safety, toleration, drug-interaction profile and efficacy, with which to guide development decisions. Due to the heterogeneous nature of alcohol dependence, the effort of developing an efficacious medication is likely to be enhanced by clearer choices about the characteristics of the population. Careful consideration of potential mechanism of action of the putative therapeutic medication should enable the appropriate choice of drinking endpoint. The pharmaceutical industry in collaboration with academia might need to develop new approaches to determining appropriate treatment endpoints with regulatory bodies. The investment risk to industry should be appraised not only in terms of the rather poor results of previous marketing efforts but with a view to the opportunity to penetrate a potentially enormous and largely untapped market.}}, author = {{Littleton, JM and De Witte, P and Litten, R and Gessa, GL and Spanagel, R and Kranzler, H and Lehert, P and Johnson, B and Saunders, J and Berglund, Mats and Harris, A and Anton, R and Mann, K}}, issn = {{1464-3502}}, language = {{eng}}, number = {{4}}, pages = {{271--275}}, publisher = {{Oxford University Press}}, series = {{Alcohol and Alcoholism}}, title = {{Challenges to medications development in treating alcohol dependence: An international perspective - Summary of a symposium held at the ESBRA Congress, Prague, 13 September 2003}}, url = {{http://dx.doi.org/10.1093/alcalc/agh067}}, doi = {{10.1093/alcalc/agh067}}, volume = {{39}}, year = {{2004}}, }